Actavis Adderall XR Approval Positive for Watson Pharm (WPI), Negative for Impax Lab (IPXL)
Tweet Send to a FriendGet Alerts SHPGY Hot Sheet
Price: $85.67 -0.2%
Rating Summary:
9 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 21 | Down: 24 | New: 29
Rating Summary:
9 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 21 | Down: 24 | New: 29
Trade SHPGY Now!
Analysts at Goldman Sachs note that news over the weekend from Shire (Nasdaq: SHPGY) that the FDA had responded to its citizen petition regarding Adderall XR generic approvability, and approved the Actavis ANDA, is positive for Watson Pharmaceuticals, Inc. (NYSE: WPI) and negative for Impax Laboratories Inc. (Nasdaq: IPXL).
"We understand that Actavis has launched, adding a full generic competitor to a market that has been divided between the brand and two supply-constrained authorized generics (IPXL and TEVA)," the analyst said.
The firm currently assumes Actavis initially captures 50% share of the market with the remaining 50% divided evenly between Shire brand and the two authorized generics. Goldman doesn't expect new entrants near term, but they will be likely by the 2nd-half of 2013.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
"We understand that Actavis has launched, adding a full generic competitor to a market that has been divided between the brand and two supply-constrained authorized generics (IPXL and TEVA)," the analyst said.
The firm currently assumes Actavis initially captures 50% share of the market with the remaining 50% divided evenly between Shire brand and the two authorized generics. Goldman doesn't expect new entrants near term, but they will be likely by the 2nd-half of 2013.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Workday (WDAY) Success Continues but Valuation Lofty, Goldman Maintains Neutral
- Compuware (CPWR) Estimates Trimmed, PT Raised at Jefferies
- Topeka Capital Starts Atmel (ATML) at Buy
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Goldman Sachs
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
